The aetiology of neuropathy in experimental diabetes

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 2, 2003, Pages 98-105

  Cameron, Norman E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Advanced glycation; Blood flow; Neuropathy; Nuclear factor kappa B; Oxidative stress; Poly (ADP ribose) polymerase; Protein kinase; Vasa nervorum; Vasodilators

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ESSENTIAL FATTY ACID; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN;

ARTICLE; AUTONOMIC NEUROPATHY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE MODEL; EXPERIMENTAL MODEL; FATTY ACID METABOLISM; GANGLION; GLYCATION; HYPERGLYCEMIA; HYPOXIA; ISCHEMIA; LIPID METABOLISM; MEDICAL INFORMATION; NERVE CONDUCTION; NERVE FIBER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERFUSION; RODENT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0041886635     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030020401     Document Type: Article

References (46)

1. Cameron NE, Eaton SEM, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 2001;44:1973-88.
2. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia 1999;42:773-88.
3. Hotta N, Koh N, Sakakibara F et al. Effect of proprionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: Comparison with an aldose reductase inhibitor. J Pharmacol Exp Ther 1996;276:49-55.
4. Schmidt RE, Plurad SB. Ultrastructural and biochemical characterisation of autonomic neuropathy in rats with chronic streptozotocin diabetes. J Neuropathol Exp Neurol 1986;45:525-44.
5. Sasaki H, Schmelzer JD, Zollman PJ, Low PA. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathologica 1997;93:118-28.
6. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Yorek MA. Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes/Metab Res Rev 2002;18:49-56.
7. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261:E1-E8.
8. Cameron NE, Cotter MA. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J Diabetes Complications 2001; 15:198-202.
9. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991;40:873-7.
10. Vinik AI, Newlon PG, Lauterio TJ et al. Nerve survival and regeneration in diabetes. Diabetes Rev 1995;3:139-57.
11. A antagonist on neurovascular function in diabetic rats: Interaction with the renin-angiotensin system. J Pharmacol Exp Ther 1996;278:1262-8.
12. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984;107:935-50.
13. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes/Metab Rev 1994;10:189-224.
14. Ritchie JM. A note on the mechanism of resistance to anoxia and ischaemia in the pathophysiological mammalian myelinated nerve. J Neurol Neurosurg Psychiatry 1985;48:274-7.
15. Cotter MA, Gibson TM, Inkster ME, Cameron NE. Effects of angiotensin converting enzyme inhibition on nerve function, neural tissue perfusion and vascular endothelium in diabetic rats. Diabetes 2002;51(suppl 2):A78.
16. Maxfield EK, Love A, Cotter MA, Cameron NE. Nerve function and regeneration in diabetic rats: effects of ZD7155, an AT1 receptor antagonist. Am J Physiol 1995;269:E530-E537.
17. Malik RA, Williamson S, Abbott C et al. Effect of the angiotensin converting enzyme inhibitor trandalopril on human diabetic neuropathy: a randomised controlled trial. Lancet 1998;352:1978-81.
18. Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care 1996;19:1091-6.
19. Litchy W, Dyck P, Tesfaye S, Zhang D, Bastyr E. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes 2002;51 (suppl 2):800.
20. Brownlee M. Biochemistry and molecular biology of diabetic complications. Nature 2001;414:813-20.
21. Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Prac 1999;45: 137-46.
22. Desco MC, Asensi M, Marquez R et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002;51:1118-24.
23. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.
24. Wolff SP. Diabetes mellitus and free radicals. Br Med Bull 1993;49:642-52.
25. Yu PH. Deamination of methylamine and angiopathy: toxicity of formaldehyde, oxidative stress and relevance of protein glycoxidation in diabetes. J Neural Trans 1998;52(suppl):201-16.
26. Ishii N, Patel KP, Lane PH et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12:1630-9.
27. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant, alpha-lipoic acid, on endothelial and neurogenic functions of corpus cavernosum in rats. Diabetologia 1999;42:343-50.
28. Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001;31: 125-35.
29. Coppey LJ, Gellett JS, Davidson EP et al. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001;134:21-9.
30. Cameron NE, Tuck Z, McCabe L, Cotter MA. Effects of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion and function in experimental diabetes. Diabetologia 2001;44:1161-9.
31. Keegan A, Cotter MA, Cameron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radic Biol Med 1999;27:536-43.
32. Cameron NE, Cotter MA. Effects of an extracellular transition metal chelator, hydroxyethyl starch-deferoxamine, on neurovascular function in diabetic rats. Diabetologia 2001;44:621-8.
33. Wada R, Nishizawa Y, Yagihashi N et al. Effects of OPB-9165, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 2001; 31:513-20.
34. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999;10:157-67.
35. Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees D. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994;37:651-63.
36. Keegan A, Jack AM, Cameron NE, Cotter MA. Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats. J Cardiovasc Pharmacol 2000;35:606-13.
37. Ford I, Cotter MA, Cameron NE, Greaves M. The effects of alpha-lipoic acid or evening primrose oil treatment on vascular risk factors, blood flow and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism 2001;50:868-75.
38. Horrobin DF. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1988;31:181-97.
39. Jack AM, Keegan A, Cotter MA, Cameron NE. Effects of diabetes and chronic evening primrose oil treatment on responses of aorta, corpus cavernosum and mesenteric vasculature in rats. Life Sci 2002;71:1863-77.
40. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66.
41. +-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999;42:1120-30.
42. Cotter MA, Jack AM, Cameron NE. Effects of the protein kinase C β-isoform inhibitor, LY333531, on neural and vascular function in streptozotocin-diabetic rats. Clin Sci 2002;103:311-21.
43. Purves T, Middlemas A, Agthong S et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001; 15:2508-14.
44. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circ Res 2001;89:684-91.
45. Obrosova IG, Abatan OI, Li F. Poly (ADP-ribosyl)ation inhibitors correct conduction velocity deficits and energy metabolism in experimental diabetic neuropathy (EDN). Diabetes 2001;50(suppl 2):A188-9.
46. Mizisin AP, Steinhardt RC, O'Brien JS, Calcutt NA. TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol 2001;60:953-60.